Other ID Studies

A5320 Viral Hepatitis C Infection Long-term Cohort Study

  • Question: Observational long-term follow-up study in hepatitis C monoinfected and HCV/HIV-1 coinfected subjects.
  • Population: Men and women who received DAA therapy for HCV as part of a clinical trial within the last 12 months. HCV monoinfected or HCV/HIV-1 coinfected. SVR or non-SVR.
  • Medication: No medication is provided. If participant is non-SVR, they may undergo repeat treatment on another clinical trial or through standard of care while enrolled in A5320
  • Duration: Q6 month visits for 5 years
  • Contact: Erin Hoffman 919-843-0720

Status: On-going / Recruiting

A5327 Sofosbuvir plus Ribavirin Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

  • Question: To evaluate HCV treatment response to SOF and RBV taken for 12 or 8 weeks as assessed by SVR12 in persons with existing HIV-1 infection who are acutely infected with any HCV genotype
  • Population:44 HIV-1 co-infected individuals who have acute HCV infection or reinfection
  • Medication: SOF 400mg daily and weight-based RBV (1000 or 1200mg daily in two divided doses)
  • Duration: 32-26 weeks (8-12 weeks on-treatment followed by 24 weeks of follow-up)
  • Contact: David Currin, RN 919-966-2624 or Pager 919-216-2406

Status: On-going / Recruiting

DMID09-0106: Experimental Human Infection with Isogenic Mutants of Neisseria gonorrhea 

  • Question: Compare ability of different engineered mutants of Neisseria gonorrhea to cause clinical infection
  • Population: Healthy men age 18-35; without history of STIs and HIV negative
  • Medication: Inoculation with suspension of Neisseria gonorrhea; treatment with IM ceftriaxone for cure
  • Duration: 6 days for inpatient stays (may leave during day); additional visit 1 week post treatment
  • Call: Susan Blevins, ANP 919-843-8763 or Chris Evans, ANP 919-843-3759

Status: On-going / Recruiting